# A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma

> **NCT04220307** · PHASE2 · COMPLETED · sponsor: **Akeso** · enrollment: 34 (actual)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **BIOLOGICAL:** AK104

## Key facts

- **NCT ID:** NCT04220307
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-26
- **Primary completion:** 2021-05-15
- **Final completion:** 2023-03-09
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04220307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04220307, "A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04220307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*